Proactive Investors - Run By Investors For Investors

Breakfast News - Switzerland Says the EU Is Trying to Weaken Its Financial Center

Breakfast News - Switzerland Says the EU Is Trying to Weaken Its Financial Center

What’s cooking in the IPO kitchen?

NEX Exchange

Whetstone Capital No raise. Due 5 January 2018. Mkt Cap £1.6m.  Investment Vehicle for small and mid sized private and public companies.



Eqtec—Company with access to a proprietary advanced gasification technology used in industrial size power plants to convert waste into synthetic gas to generate electricity.  Raising £1.6m. Mkt Cap £8.7m. Due late Dec.

Volex (LON:VLX)L—The global provider of cable assemblies is proposing to move from the main market to AIM on 19 January. £75m market cap. FYMar18E rev £241.5m and £7.19m PBT.

OnTheMarket—Intention to float on AIM to raise c.£50m which will be used to fund the growth of the portal, already the third biggest UK residential property portal provider. Expected valuation £200m to £250m.


Main Market Specialist Fund Segment

Sure Ventures  POSTPONED–Raising  up to £50m at £1. Focus on FinTech, IoT and Augmented/Virtual Reality. Due 22 Dec.

Main Market Premium Listing

GEMS Education—report by Reuters that the private schools group is seeking a $4.5bn to $5bn London float in 2018. FYAug17 rev $926.2m and adjusted EBITDA $261.6m.

Vivo Energy—The Africa-focused company, which operates around 1,800 Shell forecourts across 16 countries  reported by City A.M. to be preparing for a London float next year

Breakfast buffet

Legendary Investments (LON:LEG) 0.16p £5.1m

‘Agreement to acquire an interest in Circle Oil Tunisia Limited ("COTL"), which owns the, El Mediouni East and Central oil asset ("ELM") in the Mahdia Permit located in the Gulf of Hammamet off the Tunisian coast, in exchange for its interests in Manas Resources LLC ("Manas"). The Permit duration and work programme are in the process of being finalised.

As a result of this agreement, Legendary will receive an interest of up to 2 per cent in CTOL. Legendary's interest in Manas is valued in its books at £100,000.’

M.P Evans Group (LON:MPE) 783.8p £430m

Completion its acquisition of Sunrich Plantations Pte Ltd ("Sunrich"), which owns 95% of an Indonesian company, PT Bumi Mas Agro ("BMA"), which in turn owns an oil-palm plantation in Indonesia.  Comprises 8,240 hectares. Of this area, 7,800 hectares are young oil palms, planted mainly in 2012-17. In addition to the land acquired by the Group, as required by law in Indonesia, a smallholders' scheme is in operation. Some 1,300 hectares have already been planted and allocated to the scheme which, ultimately, should comprise 20% of the total planted area.  $40m upfront and $49.2m deferred,.

FYDec17E rev £78.5m and EPS 23.98p, div 21.17p.

SDX Energy (LON:SDX) 53p £108.4m

“The North Africa focused oil and gas company, has commenced well operations on its ELQ-1 well on the Gharb Centre permit in Morocco. The ELQ-1 well is the fourth well in the Company's nine well campaign and the first of two commitment wells planned on the Gharb Centre permit, which was acquired in June 2017 after the acquisition of Circle Oil's assets in Egypt and Morocco in January 2017.  The Gharb Centre permit is adjacent to the Company's Sebou permit with the ELQ-1 location being approximately 400 meters from the existing Sebou infrastructure. The well is anticipated to take 15-20 days to drill and if successful will be completed, flow tested and connected to existing infrastructure.” FYDec17E rec C$58.8m and PBT C$14.47m.

Westminster Group (LON:WSG) 13.5p £11.32m

Update on previously announced major long-term project opportunity in the Middle East.   Further extensive discussions have been taking place regarding priorities, order of roll-out and the client's growing requirements. All but a few more minor commercial & contractual issues have now been agreed. Due to the complexity and increasing potential scope of this project, it has  been agreed to undertake the project in phases, with the initial phase expected to be worth c. €24m per annum. Plans are in place to raise the required funds to support investment in this project and other potential new Managed Services contracts, details of which will be announced  in due course.

LXB Retail Props (LXB.L) 21.75p £35.77m

The closed-ended real estate investment company focused on edge of town and out of town retail assets, is pleased to report that it has exchanged contracts for the disposal of its two remaining investments at Stafford and to update on further lettings at Rushden Lakes and Sutton.

Riverside being sold for a headline price of £36.8m and Bridge Street for an initial £8.9m.

At Rushden lakes phase 1 lettings now complete.  On Phase 3 at Rushden, contracts have also been exchanged with Decathlon to take a 14,000 sq ft store (7,000 sq ft at ground and 7,000 sq ft at mezzanine level). The letting means a single unit of 6,000 sq ft (which could be split) remains to be let on Phase 3. Practical Completion of Phase 3 is due for June 2018.  At, Sutton Gym Group agreed to take a 12206 sq ft unit.

Angelfish Investments (NEX:ANGP) 0.063p £0.4m

“One Media Enterprises Limited ("OME"), a company in which Angelfish initially invested in 2013, has been acquired by OneLife Technologies Corp. ("OneLife") a public company listed on the OTC:US with a ticker symbol "OLMM". To facilitate the Acquisition, OME has agreed to repay in full the investment and loans made to date by Angelfish together with payment of management fees charged and an uplift on amounts due ("the Agreement"). The Agreement provides for an amount payable to Angelfish of US$1m in cash in instalments plus the issue to Angelfish of 200,000 shares of Common Stock in OneLife and warrants to subscribe for 200,000 shares of Common Stock in OneLife, exercisable at US$1 per share”.

N4 Pharma (LON:N4P) 10.69p £8.06m

The specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the filing of its Patent Cooperation Treaty ("PCT") patent application for the oral reformulation of Aprepitant (marketed by Merck & Co under the brand name Emend). Aprepitant is an anti-emetic drug used to suppress nausea resulting from surgery and chemotherapy with global sales of over $500m last year and whose patent for the oral products expired in 2015.

“Sildenafil remains our lead project for generics and in line with our stated strategy, we will continue to progress our intellectual property for other possible generic reformulation opportunities that we can then develop at a later stage.”

YOLO Leisure and Technology (LON:YOLO) 0.6p £1.99m

FY Sep17 results. “A year of progress for the investment company which now has five companies within its portfolio.”

· Total comprehensive income for the year £726,153 (2016: Loss £621,530)

· Unrealised gains on investments of £657,935 (2016: losses £372,758)

· Realised gains on disposal of investments of £270,559 (2016: £Nil)

· Total Net Assets of £4,514,025 (2016: £1,206,871), representing 1.02p per share (2016: 0.68p).

   Cash £620k.  "Yolo is well positioned as an investment company to actively grow its portfolio in 2018.  Our purpose is to identify innovative businesses that meet our investment criteria and have significant potential to deliver value for our shareholders”

Amphion Innovations (LON:AMP) 1.38p £2.85m

The developer of medical, life science, and technology businesses, announces a further update regarding its partner company Polarean Imaging Limited , in which Amphion currently has an interest of circa 26%. Further to recent  announcement of 22 November 2017, Polarean has successfully closed on £647,127 in interim funding in the form of a Convertible Promissory Note (CPN). The CPN will automatically convert into fully paid Ordinary Shares of Polarean at a conversion price equal to 90% of the Issue Price of Ordinary Shares upon Admission to trading of the Ordinary Shares to the AIM market of the London Stock Exchange. The proceeds will be used to ensure there are adequate financial resources to complete the proposed IPO which is expected in Q1 2018, market conditions permitting.

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.


© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use